lemaitre vascular inc - LMAT
LMAT
Close Chg Chg %
86.99 0.43 0.49%
Closed Market
87.42
+0.43 (0.49%)
Volume: 129.98K
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: lemaitre vascular inc - LMAT
LMAT Key Data
| Open $87.16 | Day Range 86.81 - 88.73 |
| 52 Week Range 71.42 - 105.55 | Market Cap $1.97B |
| Shares Outstanding 22.69M | Public Float 20.82M |
| Beta 0.71 | Rev. Per Employee N/A |
| P/E Ratio 37.43 | EPS $2.36 |
| Yield 91.96% | Dividend $0.20 |
| EX-DIVIDEND DATE Nov 20, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 136.71K |
LMAT Performance
| 1 Week | 2.88% | ||
| 1 Month | 2.85% | ||
| 3 Months | 0.69% | ||
| 1 Year | -10.79% | ||
| 5 Years | 81.11% |
LMAT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About lemaitre vascular inc - LMAT
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.
LMAT At a Glance
LeMaitre Vascular, Inc.
63 Second Avenue
Burlington, Massachusetts 01803
| Phone | 1-781-221-2266 | Revenue | 219.86M | |
| Industry | Medical Specialties | Net Income | 44.04M | |
| Sector | Health Technology | 2024 Sales Growth | 13.634% | |
| Fiscal Year-end | 12 / 2025 | Employees | 664 | |
| View SEC Filings |
LMAT Valuation
| P/E Current | 37.433 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 47.659 |
| Price to Sales Ratio | 9.546 |
| Price to Book Ratio | 6.16 |
| Price to Cash Flow Ratio | 47.57 |
| Enterprise Value to EBITDA | 32.014 |
| Enterprise Value to Sales | 9.028 |
| Total Debt to Enterprise Value | 0.094 |
LMAT Efficiency
| Revenue/Employee | 331,118.976 |
| Income Per Employee | 66,322.289 |
| Receivables Turnover | 7.313 |
| Total Asset Turnover | 0.489 |
LMAT Liquidity
| Current Ratio | 12.847 |
| Quick Ratio | 11.019 |
| Cash Ratio | 9.793 |
LMAT Profitability
| Gross Margin | 66.003 |
| Operating Margin | 23.828 |
| Pretax Margin | 25.868 |
| Net Margin | 20.03 |
| Return on Assets | 9.802 |
| Return on Equity | 13.866 |
| Return on Total Capital | 8.421 |
| Return on Invested Capital | 10.55 |
LMAT Capital Structure
| Total Debt to Total Equity | 55.052 |
| Total Debt to Total Capital | 35.506 |
| Total Debt to Total Assets | 33.65 |
| Long-Term Debt to Equity | 54.257 |
| Long-Term Debt to Total Capital | 34.993 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lemaitre Vascular Inc - LMAT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 154.42M | 161.65M | 193.48M | 219.86M | |
Sales Growth
| +19.37% | +4.68% | +19.69% | +13.63% | |
Cost of Goods Sold (COGS) incl D&A
| 59.24M | 62.94M | 72.53M | 74.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 9.47M | 9.43M | 9.52M | 9.61M | |
Depreciation
| 3.28M | 3.25M | 3.42M | 3.82M | |
Amortization of Intangibles
| 6.20M | 6.18M | 6.09M | 5.79M | |
COGS Growth
| +18.97% | +6.25% | +15.24% | +3.06% | |
Gross Income
| 95.19M | 98.71M | 120.96M | 145.12M | |
Gross Income Growth
| +19.62% | +3.70% | +22.53% | +19.97% | |
Gross Profit Margin
| +61.64% | +61.07% | +62.52% | +66.00% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 58.76M | 68.93M | 83.88M | 92.73M | |
Research & Development
| 11.80M | 13.29M | 16.97M | 15.65M | |
Other SG&A
| 46.96M | 55.64M | 66.91M | 77.08M | |
SGA Growth
| +14.64% | +17.30% | +21.68% | +10.55% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 2.95M | 370.00K | 134.00K | |
EBIT after Unusual Expense
| 36.42M | 26.83M | 36.71M | 52.26M | |
Non Operating Income/Expense
| 81.00K | 661.00K | 2.76M | 4.82M | |
Non-Operating Interest Income
| 197.00K | 986.00K | 3.08M | 4.95M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.22M | 205.00K | - |
Interest Expense Growth
| - | - | +69.39% | -100.00% | - |
Gross Interest Expense
| - | - | 2.22M | 205.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 34.29M | 27.49M | 39.48M | 56.88M | |
Pretax Income Growth
| +25.34% | -19.82% | +43.60% | +44.08% | |
Pretax Margin
| +22.20% | +17.01% | +20.40% | +25.87% | |
Income Tax
| 7.38M | 6.85M | 9.37M | 12.84M | |
Income Tax - Current - Domestic
| 6.01M | 6.00M | 7.50M | 12.15M | |
Income Tax - Current - Foreign
| 1.29M | 1.03M | 1.08M | 1.14M | |
Income Tax - Deferred - Domestic
| 54.00K | (227.00K) | 738.00K | (457.00K) | |
Income Tax - Deferred - Foreign
| 25.00K | 45.00K | 45.00K | 6.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 26.91M | 20.64M | 30.11M | 44.04M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 26.91M | 20.64M | 30.11M | 44.04M | |
Net Income Growth
| +26.80% | -23.31% | +45.89% | +46.28% | |
Net Margin Growth
| +17.42% | +12.77% | +15.56% | +20.03% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 26.91M | 20.64M | 30.11M | 44.04M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 26.91M | 20.64M | 30.11M | 44.04M | |
EPS (Basic)
| 1.2718 | 0.9391 | 1.355 | 1.9614 | |
EPS (Basic) Growth
| +21.34% | -26.16% | +44.29% | +44.75% | |
Basic Shares Outstanding
| 21.16M | 21.98M | 22.22M | 22.45M | |
EPS (Diluted)
| 1.253 | 0.9308 | 1.3426 | 1.9333 | |
EPS (Diluted) Growth
| +20.92% | -25.71% | +44.24% | +44.00% | |
Diluted Shares Outstanding
| 21.48M | 22.17M | 22.42M | 22.78M | |
EBITDA
| 45.90M | 39.22M | 46.60M | 62.00M | |
EBITDA Growth
| +25.61% | -14.56% | +18.82% | +33.05% | |
EBITDA Margin
| +29.72% | +24.26% | +24.08% | +28.20% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 103.667 | |
| Number of Ratings | 11 | Current Quarters Estimate | 0.619 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 2.584 | |
| Last Quarter’s Earnings | 0.67 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.447 | Next Fiscal Year Estimate | 2.824 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 11 | 7 |
| Mean Estimate | 0.62 | 0.66 | 2.58 | 2.82 |
| High Estimates | 0.66 | 0.70 | 2.83 | 3.13 |
| Low Estimate | 0.54 | 0.62 | 2.39 | 2.66 |
| Coefficient of Variance | 6.23 | 4.77 | 4.25 | 5.89 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 5 | 5 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Lemaitre Vascular Inc - LMAT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lemaitre Vascular Inc - LMAT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,873,651 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.77 per share | 158,829,395.27 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 20,373 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 16,269 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 7,733 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 7,836 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,827,003 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.69 per share | 154,728,884.07 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,828,102 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.24 per share | 155,827,414.48 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,831,402 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.65 per share | 100,086,119.30 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,825,220 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $47.19 per share | 86,132,131.80 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,818,145 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $48.6 per share | 88,361,847.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,810,411 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $37.29 per share | 67,510,226.19 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,802,575 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $35.48 per share | 63,955,361.00 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,796,783 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.94 per share | 152,618,748.02 |
| May 21, 2025 | George W. LeMaitre Chairman and CEO; Director | 1,802,483 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.86 per share | 154,761,190.38 |
| Mar 24, 2025 | Dorian LeBlanc Chief Financial Officer | 1,221 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Trent G. Kamke Senior V. P., Operations | 1,044 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $80.25 per share | 83,781.00 |
| Mar 17, 2025 | Trent G. Kamke Senior V. P., Operations | 2,397 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $35.48 per share | 85,045.56 |
| Mar 17, 2025 | Trent G. Kamke Senior V. P., Operations | 7,573 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $23.56 per share | 178,419.88 |
| Mar 17, 2025 | Trent G. Kamke Senior V. P., Operations | 5,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $82.12 per share | 456,915.68 |